Randomised, phase 1 evaluation of the safety, tolerability, pharmacokinetics and pharmacodynamics of iptacopan in healthy volunteers
These results characterise the pharmacokinetics/pharmacodynamics of iptacopan in healthy volunteers; the data helped build semi-mechanistic population pharmacokinetic/pharmacodynamic models, which guided the accelerated clinical development of iptacopan.
Authors
- Anna Schubart (ORCID: https://orcid.org/0000-0003-4253-0600)
- Irina Baltcheva
- Kenneth Kulmatycki (ORCID: https://orcid.org/0000-0003-2002-3966)
- Robert Schmouder (ORCID: https://orcid.org/0000-0001-9896-7305)
- Dr Guido Junge
- Marie‐Anne Valentin
Institutions
- Novartis (Switzerland) (CH)
- Novartis (United States) (US)
- Novartis Institutes for BioMedical Research
Publication Details
- Journal
- British Journal of Pharmacology
- Published
- 2026-02-17
- DOI
- https://doi.org/10.1111/bph.70339
- Primary Topic
- Complement system in diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Novartis Pharmaceuticals Corporation